Researcher Develops Innovative Tool for Early Cancer Detection

A childhood friend’s battle with cancer has inspired research that could lead to more precise early-stage cancer diagnoses. Dr. Judy Ann Cocadiz, a researcher at the University of Otago in South Island, New Zealand, has been awarded a three-year, $300,000 post-doctoral fellowship from the Cancer Society. This funding will support her project focused on developing a new diagnostic tool that targets circulating tumour DNA (ctDNA), fragments of DNA released by cancer cells into the bloodstream.

Cocadiz’s research aims to create a small device that can be inserted into a blood vessel to act as a “sieve,” capturing ctDNA for a brief period. Current methods require drawing blood samples, which typically yield only 8-10 ml of blood. In early-stage cancers, the ctDNA concentration is often too low to detect, making diagnosis challenging. Cocadiz noted, “It is like looking for a needle in a haystack, essentially.”

The new device, functioning similarly to an intravenous (IV) line, would allow for a more efficient collection of ctDNA without the need for extensive blood draws. This innovation could significantly reduce patient discomfort, especially for vulnerable groups such as children or individuals with health complications. Cocadiz emphasized the importance of minimizing physical strain on patients while enhancing diagnostic capabilities.

Currently, her research remains in the proof-of-concept stage. Cocadiz expressed optimism about the potential impact, stating, “I am really optimistic about where my research is heading.” She credits the Cancer Society grant not only for supporting her project but also for nurturing the early stages of her career in cancer research.

Cocadiz’s interest in cancer research was sparked during her early childhood in the Philippines. At the age of five, she noticed that her best friend frequently had large bruises from minor injuries. After informing her parents, a visit to the doctor revealed that her friend had early-stage leukaemia. Thanks to timely diagnosis and treatment, he has since recovered. Reuniting with him earlier this year, Cocadiz was delighted to find him healthy and thriving.

After completing her PhD in biochemistry last year, Cocadiz decided against pursuing a career as a doctor. Instead, she focused on research that could contribute to better outcomes for cancer patients. “Everything just kind of fell into place, and I am really glad I ended up in cancer research,” she reflected.

Cocadiz’s innovative approach could pave the way for advancements in cancer diagnostics, offering hope to patients and healthcare professionals alike. While the path to clinical application may take years, the potential benefits of her work are significant, underscoring the importance of continued investment in cancer research initiatives.